Mantle Cell Lymphoma

Within 6 months of receiving induction chemotherapy, consolidation treatment with autologous hematopoietic cell transplantation correlated with a significant improvement in progression-free survival in younger, fit patients with mantle cell lymphoma.

Krish Patel, MD, discusses some of the most significant mantle cell lymphoma data presented during the 2018 ASH Annual Meeting and how the use of BTK inhibitors will evolve going forward.

The FDA has granted the investigational BTK inhibitor zanubrutinib a breakthrough therapy designation for the treatment of adult patients with mantle cell lymphoma who have previously received at least 1 prior therapy.

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses the promise of acalabrutinib in the treatment of patients with mantle cell lymphoma.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses next steps for research with acalabrutinib in mantle cell lymphoma.

Over the past 2 decades, considerable efforts have focused on the development of therapies that can restore apoptosis in malignant cells.

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses the safety of acalabrutinib (Calquence) plus bendamustine and rituximab (BR; Rituxan) in patients with mantle cell lymphoma (MCL).

The understanding of the BCL2 oncogene and the BCL-2 protein family have motivated the current advancements in cancer therapeutics that target different members of apoptotic regulatory networks.

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses differences between BTK inhibitors in mantle cell lymphoma (MCL).

Michael Wang, MD, discusses the promise of single-agent acalabrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the safety and efficacy of single-agent acalabrutinib in the treatment of mantle cell lymphoma.

Robert Dean, MD, staff physician, Cleveland Clinic, discusses FDA approved drugs for patients with relapsed mantle cell lymphoma.

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses an emerging combination in the treatment of patients with mantle cell lymphoma.

The frontline induction treatment of bendamustine and rituximab has improved event-free surviva compared with R-CHOP therapy in patients with mantle cell lymphoma.

Tycel J. Phillips, MD, discusses the clinical implications of acalabrutinib plus bendamustine and rituximab for patients with mantle cell lymphoma.

Single-agent venetoclax (Venclexta) led to durable responses in patients with relapsed/refractory mantle cell lymphoma with a low rate of late-onset toxicities.